Business Wire

IBC

19.9.2018 12:05:11 CEST | Business Wire | Press release

Share
IBC Grows in Scope, Reach and Diversity

IBC2018 has closed its doors for this year and has delivered another great event with visitor figures of 55,884. As well as providing a host of new initiatives this year, the exhibition grew by 667m2 and conference delegates were up by 14% year on year. One of the most important growth figures lies in the diversity of its content with a targeted effort increasing women speakers at the conference up from 14% to 37%.

The IBC International Honour for Excellence saw its first-ever woman recipient this year, too. Joan Ganz Cooney was the co-creator of the global phenomenon that is Sesame Street , 50 years ago and her trophy was collected on her behalf by one of the street’s longest residents, Ernie.

The IBC App has provided real networking opportunities, with more than 91,000 interactions on the matchmaking platform. In addition, IBC trended number one on Twitter in the Netherlands on several days of the convention, with 185 million potential impressions and over 250,000 video views. Engagement with IBC has also increased on a year-round basis with IBC365 – the site now has over 55,000 subscribers averaging 49,000 active users per month.

Michael Crimp, IBC’s CEO, comments; “The show is about engagement, engagement, engagement. The stats are up in almost all areas and re-bookings are ahead of last year. IBC is much more than a trade show, we have developed a basket of data-driven statistics including sales leads generated on stands, conference attendance and IBC365 views and this sharing of information is pivotal to the longevity of IBC’s success and sits at the core of the organisation.”

“All of the initiatives this year have been aimed at bringing together the best minds, the original thinkers, to network and share their knowledge. As all communication becomes video and audio, IBC continues to be the place to debate the future of media, technology and entertainment,” adds Crimp.

Guiding the renewed focus this year was a new content steering group, drawn from across the industry, and chaired by Keith Underwood, Chief Operating Officer at Channel 4 in the UK.

IBC head of content Jaisica Lapsiwala, said, “This year, we have worked closely with the industry to create a programme that is not only reflective of the changes in the ecosystem, but which also paves a path forward for our industry. This has resulted in an engaging and diverse 2018 edition of IBC. An example of this was our Global Gamechangers day which brought creative, technology and business chiefs such as Zahra Rasool from Al Jazeera, Peter Salmon from Endemol and Lindsay Pattison from WPP to the stage. Threaded through the programme were the cutting-edge technologies transforming the industry. Blockchain is a great example, with a keynote from Kim Jackson of Singular DTV and papers from people who are already implementing it, like Éric Minoli of Groupe Média TFO.”

Alongside the conference, IBC hosted three invitation-only executive forums. The Leaders’ Forum looked to the future, considering what the new ecosystem could be following consolidation, acquisition and collaboration. The Cyber Security Forum considered not just the threats but how to respond to them. New to the programme this year was the Telco and Media Innovation Forum, a vital point of debate as the boundaries between media and communication blur.

Once again, IBC was the venue for an examination of the intersection of craft and technology in The Big Screen. Sessions included an in-depth look at the effects in Game of Thrones and Pixar’s Dominic Glynn talking about the animation marvel that is The Incredibles 2 – and how things have changed in the 14 years since the original movie.

The Future Zone is always a busy part of IBC, with presentations from researchers and academic bodies developing the ideas which may become the hit products five years from now. This year saw the addition of a theatre stage, presented by one of IBC’s owners, IABM, with a rolling programme of presentations discussing the ideas in more detail.

As well as the IBC Big Screen, the IABM Future Trends Theatre and the Content Everywhere Hub, staged presentations and enlarged on-stand meeting areas are becoming an increasingly common feature of exhibition stands throughout the show. “As the industry has moved on from big boxes handling discrete functions towards a software-based world that looks across the content supply chain, so the way vendors present themselves and interact with visitors at IBC has changed,” said Roger Thornton, chair of the IBC exhibition committee.

“Today, it’s all about collaboration to deliver solutions that give broadcast and media companies the agility and flexibility they need to keep ahead in this rapidly transforming media landscape. That’s why we’re seeing more and more companies using big-picture theatre presentations on their stands and providing large meeting areas where the conversations that kick off the collaboration get started.”

IBC2019 starts with the first day of conference sessions on Thursday 12 September, running until the exhibition closes on Tuesday 17 September.

-ENDS-

Notes to Editors:

About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.

IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.

IBC2019 Dates

Conference:       12 - 16 September 2019
Exhibition: 13 - 17 September 2019

For more information about IBC2019 visit: show.ibc.org/

Contact:

Bubble Agency Louise Wells E: louisew@bubbleagency.com T: +44 7718 985 252

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye